Financial News
Proqr Therapeutics (NQ: PRQR )
2.140
+0.020
(+0.94%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
All News about Proqr Therapeutics
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
Via GlobeNewswire
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
![](https://cdn.benzinga.com/files/images/story/2023/03/30/safe__green_holdings_-_logo.jpg?width=1200&height=800&fit=crop)
![](/next-assets/images/schema-image-default.png)
Earnings Outlook For ProQR Therapeutics
March 28, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/08/12/aapharma_15.png?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/03/30/bed_bath__beyond_-__logo.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/03/29/image36.jpeg?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/726381/optometrist-covering-her-patients-eyes-with-an-occluder-during-an-eye-exam.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/03/29/kodiak_sciences_-_logo.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/03/29/image34.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/03/29/image49.jpg?width=1200&height=800&fit=crop)
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
Via GlobeNewswire
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
February 28, 2023
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2022/12/23/image-tesla4_0.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/12/22/image34.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2021/12/sklz-1600-1024x576.png)
![](https://cdn.benzinga.com/files/images/story/2022/12/22/image20.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/10/electric-vehicle-charging-ev-1600.jpg)
![](https://investorplace.com/wp-content/uploads/2020/03/mrna1600.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/12/22/image21.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/12/22/image20.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/12/22/prqr_logo_light__4f1694c259509189da1a8fac435f46e0.png?width=1200&height=800&fit=crop)
ProQR Therapeutics Shares Soar As Eli Lilly Expands RNA Collaboration
December 22, 2022
Via Benzinga
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street-washington-statue.jpg)
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
December 22, 2022
Via GlobeNewswire
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
ProQR Announces Third Quarter 2022 Operating and Financial Results
November 09, 2022
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.